» Articles » PMID: 37066909

Partial Least Squares Regression Analysis of Alzheimer's Disease Biomarkers, Modifiable Health Variables, and Cognitive Change in Older Adults with Mild Cognitive Impairment

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2023 Apr 17
PMID 37066909
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prior work has shown that certain modifiable health, Alzheimer's disease (AD) biomarker, and demographic variables are associated with cognitive performance. However, less is known about the relative importance of these different domains of variables in predicting longitudinal change in cognition.

Objective: Identify novel relationships between modifiable physical and health variables, AD biomarkers, and slope of cognitive change over two years in a cohort of older adults with mild cognitive impairment (MCI).

Methods: Metrics of cardiometabolic risk, stress, inflammation, neurotrophic/growth factors, and AD pathology were assessed in 123 older adults with MCI at baseline from the Alzheimer's Disease Neuroimaging Initiative (mean age = 73.9; SD = 7.6; mean education = 16.0; SD = 3.0). Partial least squares regression (PLSR)-a multivariate method which creates components that best predict an outcome-was used to identify whether these physiological variables were important in predicting slope of change in episodic memory or executive function over two years.

Results: At two-year follow-up, the two PLSR models predicted, respectively, 20.0% and 19.6% of the variance in change in episodic memory and executive function. Baseline levels of AD biomarkers were important in predicting change in both episodic memory and executive function. Baseline education and neurotrophic/growth factors were important in predicting change in episodic memory, whereas cardiometabolic variables such as blood pressure and cholesterol were important in predicting change in executive function.

Conclusion: These data-driven analyses highlight the impact of AD biomarkers on cognitive change and further clarify potential domain specific relationships with predictors of cognitive change.

Citing Articles

Neuronal and glial dysfunction, white matter hyperintensities and cognition in ageing and Alzheimer's disease.

Lee A, Howard E, Saltiel N, Hayes J, Hayes S Brain Commun. 2025; 7(1):fcaf068.

PMID: 39995657 PMC: 11848269. DOI: 10.1093/braincomms/fcaf068.

References
1.
Hu W, Chen-Plotkin A, Arnold S, Grossman M, Clark C, Shaw L . Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010; 119(6):669-78. PMC: 2880811. DOI: 10.1007/s00401-010-0667-0. View

2.
Verberk I, Hendriksen H, Van Harten A, Wesselman L, Verfaillie S, van den Bosch K . Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging. 2020; 89:99-107. DOI: 10.1016/j.neurobiolaging.2020.01.007. View

3.
Fjell A, Walhovd K, Fennema-Notestine C, McEvoy L, Hagler D, Holland D . CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci. 2010; 30(6):2088-101. PMC: 2828879. DOI: 10.1523/JNEUROSCI.3785-09.2010. View

4.
Jefferson A, Gibbons L, Rentz D, Carvalho J, Manly J, Bennett D . A life course model of cognitive activities, socioeconomic status, education, reading ability, and cognition. J Am Geriatr Soc. 2011; 59(8):1403-11. PMC: 3222272. DOI: 10.1111/j.1532-5415.2011.03499.x. View

5.
Balietti M, Giuli C, Casoli T, Fabbietti P, Conti F . Is Blood Brain-Derived Neurotrophic Factor a Useful Biomarker to Monitor Mild Cognitive Impairment Patients?. Rejuvenation Res. 2020; 23(5):411-419. DOI: 10.1089/rej.2020.2307. View